ProCE Banner Activity

Choosing the Right VMAT2 Inhibitor for TD

Clinical Thought
The availability of 2 FDA-approved agents for the treatment of tardive dyskinesia has been a tremendous accomplishment. In this ClinicalThought, I explore the choices of FDA-approved agents to treat tardive dyskinesia and review what to consider.

Released: November 19, 2021

Expiration: November 18, 2022

Share

Faculty

Sanjay Gupta

Sanjay Gupta, MD

Adult and Geriatric Psychiatry
Chief Medical Officer, BryLin Behavioral Health System
Medical Director, Endeavor Health Services
Voluntary Professor, Department of Psychiatry
SUNY at Buffalo, SUNY Upstate Medical University at Syracuse
Psychiatry Division Chief, Supportive and Palliative Care Department
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant provided by

Neurocrine Biosciences

Faculty Disclosure

Primary Author

Sanjay Gupta, MD

Adult and Geriatric Psychiatry
Chief Medical Officer, BryLin Behavioral Health System
Medical Director, Endeavor Health Services
Voluntary Professor, Department of Psychiatry
SUNY at Buffalo, SUNY Upstate Medical University at Syracuse
Psychiatry Division Chief, Supportive and Palliative Care Department
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Sanjay Gupta, MD, has disclosed that he has received consulting fees from Intra-Cellular and fees for non-CME/CE services from AbbVie, Alkermes, Intra-Cellular, Janssen, Neurocrine, Otsuka, and Sunovion.